This document discusses using direct-to-patient methods in research to increase efficiency and reduce costs. It provides examples of case studies where direct-to-patient approaches were used to collect patient-reported outcomes and medical data. Direct recruitment of patients can speed up enrollment, lower costs by reducing the need for clinical sites, and provide insights from the patient perspective. However, questions remain about data quality without physician involvement and regulatory requirements are still being defined. Overall, direct-to-patient innovation holds potential to drive greater efficiencies in research.
Dr Martin Bardsley: Use of Retrospective Matching Methods 30 June 2014Nuffield Trust
Martin Bardsley, Director of Research, Nuffield Trust explores the use of retrospective matching methods to study health services and other sectors.
Dr Martin Bardsley spoke at the Nuffield Trust event: The future of the hospital, in June 2014.
Best Practices for a Data-driven Approach to Test UtilizationViewics
Would you like to learn how data-driven interventions can improve laboratory test utilization in your organization? Would you like to hear about the impact that leading hospitals/health systems and managed care organizations have made through these interventions?
If so, you might be interested in this presentation by utilization management expert Dr. Michael Astion, Medical Director at the Department of Laboratories at Seattle Children’s Hospital and Clinical Professor of Laboratory Medicine at the University of Washington.
In this presentation, Dr. Astion discusses the current state of the misuse of laboratory testing in the United States and some of the interventions that are being implemented to improve it. He covers a number of common areas of unnecessary testing — from pure abuse to tests that could be useful but are ordered inappropriately.
You'll learn about:
• Two areas of laboratory testing where misordering of tests occur frequently
• Three interventions to improve the value of testing for patients
• The role of genetic counselors and other laboratory professionals in improving lab test ordering
• The national endeavor known as PLUGS, the Pediatric Laboratory Utilization Guidance Service
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
Clinical Trials Conduct and Protocol Compliance in AsiaMedpace
This presentation focuses on health issues in Asia Pacific (specifically China), clinical trial challenges - operational and regulatory, and key considerations when conducting trials within this region.
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years.
Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions.
Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD.
You’ll learn:
• How CKD is burdening our healthcare system, and the need for better care management tools
• How the Kidney Failure Risk Equation was researched, developed, and validated
• How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians
Dr Martin Bardsley: Use of Retrospective Matching Methods 30 June 2014Nuffield Trust
Martin Bardsley, Director of Research, Nuffield Trust explores the use of retrospective matching methods to study health services and other sectors.
Dr Martin Bardsley spoke at the Nuffield Trust event: The future of the hospital, in June 2014.
Best Practices for a Data-driven Approach to Test UtilizationViewics
Would you like to learn how data-driven interventions can improve laboratory test utilization in your organization? Would you like to hear about the impact that leading hospitals/health systems and managed care organizations have made through these interventions?
If so, you might be interested in this presentation by utilization management expert Dr. Michael Astion, Medical Director at the Department of Laboratories at Seattle Children’s Hospital and Clinical Professor of Laboratory Medicine at the University of Washington.
In this presentation, Dr. Astion discusses the current state of the misuse of laboratory testing in the United States and some of the interventions that are being implemented to improve it. He covers a number of common areas of unnecessary testing — from pure abuse to tests that could be useful but are ordered inappropriately.
You'll learn about:
• Two areas of laboratory testing where misordering of tests occur frequently
• Three interventions to improve the value of testing for patients
• The role of genetic counselors and other laboratory professionals in improving lab test ordering
• The national endeavor known as PLUGS, the Pediatric Laboratory Utilization Guidance Service
Tackling the U.S. Healthcare System’s Infectious Disease Management ProblemViewics
The United States healthcare system has a serious infectious disease management problem. The antibiotic resistance crisis is widespread, serious, costly, and deadly. Delays in pathogen identification lead to poor clinical outcomes, including increased mortality risk. And, optimally managing outbreaks is critical to health systems whose reimbursement is tied to the health of a population, such as ACOs.
Eleanor Herriman, MD, MBA, Chief Medical Informatics Officer at Viewics led an informative panel discussion with industry leaders on the issues surrounding the infectious disease management crisis. Margret Oethinger, MD, Ph.D., Medical Director of Providence Health & Services, and Susan E. Sharp, Ph.D., DABMM, FAAM, Regional Director of Microbiology and the Molecular Infectious Disease Laboratories, Department of Pathology, Kaiser Permanente and President-Elect, American Society for Microbiology cover the current state of infectious disease management in the U.S., and what can be done to improve it.
You’ll learn about:
• The magnitude of the U.S. health system’s infectious disease management problem
• The most serious concerns and trends for healthcare institutions and communities across the nation
• The most promising solutions to health systems’ most urgent infectious disease management challenges
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
Clinical Trials Conduct and Protocol Compliance in AsiaMedpace
This presentation focuses on health issues in Asia Pacific (specifically China), clinical trial challenges - operational and regulatory, and key considerations when conducting trials within this region.
Revolutionizing Renal Care With Predictive Analytics for CKDViewics
Chronic Kidney Disease (CKD) is a common and growing condition, affecting about half of the Medicare population and of diabetics. In the United States, the lifetime risk of CKD for 30-year-olds is now greater than half, and the prevalence of CKD is projected to rise significantly over the next 15 years.
Current methods of predicting which CKD patients will progress to renal failure and require dialysis or transplant have low accuracy rates, causing great anxiety and suboptimal care. Without accurate risk prediction, many patients are over-treated, effectively wasting limited resources and negatively impacting outcomes. Conversely, other patients may receive inadequate treatment, restricting options to only the most costly and least desirable interventions.
Watch this on-demand webinar with Dr. Navdeep Tangri, developer of the Kidney Failure Risk Equation, which revolutionizes the way CKD patients are managed by leveraging laboratory data to accurately predict the risk of kidney failure in patients with CKD.
You’ll learn:
• How CKD is burdening our healthcare system, and the need for better care management tools
• How the Kidney Failure Risk Equation was researched, developed, and validated
• How Viewics is implementing CKD predictive analytics to automatically deliver risk information to clinicians and issue customized, educational reports to patients and clinicians
Advanced Lab Analytics for Patient Blood Management ProgramsViewics
Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem.
Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals.
Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance.
Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs.
You’ll learn:
• How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools
• New guidelines restricting red blood cell transfusions
• The role of advanced lab analytics in PBM programs
• How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
In pursuit of the 90–90–90 goals, emphasis has been placed on accelerating centralized laboratory HIV viral load testing of a population that is largely rural and decentralized. Successful
outcome requires effective specimen transport, laboratory testing, and results delivery. This paper focuses on the methods currently employed for results delivery. New innovations in this area are
yielding mixed results; we analyze different approaches and estimate the impact of each on achieving the third ‘90.’
Development of the Gestational Diabetes Registry at CMDHB (New Zealand) using...Koray Atalag
This is the prezo I have at the Australasian Long-Term Conditions Conference in Auckland on 30 Jul 2014. Focus was on prevention and management of long term conditions and use of clinical registries has proven to be effective. This is a pilot project at a large healthcare provider organisation in Auckland (Counties Manukau District Health Board) where we used the full openEHR stack to build web based front end with the OceanEHR backend.
With almost half of oncology studies failing due to a lack of patient retention, there is a critical need to develop more efficient and patient focused strategies. Jessica Thilaganathan at CRF Health sits down with International Clinical Trials to explain why electronic clinical outcome solutions could be the answer. (Published with permission of International Clinical Trials).
Patient Perspectives on Lay Trial Results SummariesCISCRP Page
This presentation will be presented by Behtash Bahador, CISCRP's Senior Manager of Quality and Compliance at the Disclosure & Transparency for Clinical Data Summit on August 13-14, 2018. To learn more at CISCRP's Lay Summaries visit www.ciscrp.org or contact Jay Matthews at jmatthews@ciscrp.org.
Advanced Lab Analytics for Patient Blood Management ProgramsViewics
Reports indicate that 30 – 70% of blood transfusions are inappropriate. Inappropriate blood transfusions put patients at increased risk of post-surgical infections, multi-system organ failure, longer hospital stays, and higher mortality rates. The transfusion guidelines most clinicians learned in their training are now outdated. As such, blood transfusion practices vary widely, and overutilization remains a major quality and cost problem.
Patient Blood Management (PBM) programs are designed to optimize the use of transfusions through a team-based approach, evidence-based guidelines, and algorithms that together guide decisions regarding specifically which patients and clinical procedures warrant blood products, and how much to transfuse. PBM programs have been quite successful in improving patient morbidity and mortality outcomes and generating millions of dollars in savings for hospitals.
Laboratory analytics can be an effective means of instituting restrictive transfusion programs, and advanced lab analytics can be critical in implementing PBM programs, as lab testing and tracking blood usage is central to decision making, changing behavior, and improving performance.
Watch a presentation by Dr. Eleanor Herriman, Chief Medical Informatics Officer at Viewics. She unveils a new suite of advanced analytics tools that support PBS and other restrictive blood management programs, enabling health systems to better leverage their valuable lab medicine assets and fully integrate this key service line into these programs.
You’ll learn:
• How inappropriate blood transfusions are burdening our healthcare system, and the need for better utilization management tools
• New guidelines restricting red blood cell transfusions
• The role of advanced lab analytics in PBM programs
• How Viewics is leveraging advanced lab analytics to help health systems more easily and cost-effectively implement PBM programs
Racing for results: lessons learnt in improving the efficiency of HIV VL and ...SystemOne
In pursuit of the 90–90–90 goals, emphasis has been placed on accelerating centralized laboratory HIV viral load testing of a population that is largely rural and decentralized. Successful
outcome requires effective specimen transport, laboratory testing, and results delivery. This paper focuses on the methods currently employed for results delivery. New innovations in this area are
yielding mixed results; we analyze different approaches and estimate the impact of each on achieving the third ‘90.’
Development of the Gestational Diabetes Registry at CMDHB (New Zealand) using...Koray Atalag
This is the prezo I have at the Australasian Long-Term Conditions Conference in Auckland on 30 Jul 2014. Focus was on prevention and management of long term conditions and use of clinical registries has proven to be effective. This is a pilot project at a large healthcare provider organisation in Auckland (Counties Manukau District Health Board) where we used the full openEHR stack to build web based front end with the OceanEHR backend.
With almost half of oncology studies failing due to a lack of patient retention, there is a critical need to develop more efficient and patient focused strategies. Jessica Thilaganathan at CRF Health sits down with International Clinical Trials to explain why electronic clinical outcome solutions could be the answer. (Published with permission of International Clinical Trials).
Patient Perspectives on Lay Trial Results SummariesCISCRP Page
This presentation will be presented by Behtash Bahador, CISCRP's Senior Manager of Quality and Compliance at the Disclosure & Transparency for Clinical Data Summit on August 13-14, 2018. To learn more at CISCRP's Lay Summaries visit www.ciscrp.org or contact Jay Matthews at jmatthews@ciscrp.org.
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...Azierta
Farmacovigilancia:
Pharmacovigilance System Master File (PSMF)
Archivo maestro de farmacovigilancia
Good vigilance Practices (GVP)
buenas practicas de farmacovigilancia
Azierta. Consultoría y asesoría científica. Farmacovigilancia España.
Across Health Multichannel Maturometer 2015Across Health
To view the recorded webinar please visit: http://bit.ly/1cLENV1
We are pleased to present you with the 7th Across Health survey on multichannel in life sciences, previously known as the Barometer.
We renamed it to the Maturometer, to reflect the content more aptly. Indeed, we have revamped and simplified the Barometer, by clustering all questions around 4 key dimensions of digital maturity: strategy & organization, business processes & technology, multichannel integration and measurement. We trust this will give you a structured view and will provide you with actionable input to take your company to the next level.
Generally speaking, the 2015 results are in line with 2014 – with historically low satisfaction levels and the 4th consecutive year of plateauing budgets (at a low level). US and Europe are most pessimistic; emerging markets appear to be more positive overall – but that may be due to their relatively new entry into this space.
We do see however a difference in speed in the market – around 14% is implementing multichannel very quickly, is spending significantly more than the average, and feels comfortable with impact measurement etc…multichannel @ multispeed!
We trust that these early leaders will soon be followed by the early majority…my guess is that 2015 REALLY is the end of the beginning!
Fonny Schenck
CEO, Across Health
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...Azierta
El modulo VII de las GVP define como se debe realizar un PSUR, con el fin de actualizar el balance riesgo-beneficio de un medicamento.
Con estos módulos, la EMA busca garantizar la seguridad y eficacia de los medicamentos.
Farmacovigilancia: Vision general de la farmacovigilanciaAzierta
Farmacovigilancia:
Que es la farmacovigilancia. farmacovigilancia definicion. Farmacovigilancia concepto
GPV definiciones conceptos legislacion principios organismos. Repaso general sobre todos los temas relacionados con la farmacovigilancia:
Breve introducción sobre el concepto segun la OMS.
Evolución histórica y sucesos más importantes.
Conceptos y definiciones.
Metodología.
Organismos reguladores más importantes.
Legislación.
GVP: Good Vigilance Practices. Modulos sobre las buenas prácticas en farmacovigilancia y breve descripción de cada uno de ellos.
Conclusiones.
Azierta. Consultoria y asesoria farmaceutica. Farmacovigilancia España
Across Health Multichannel Maturometer 2016Across Health
We are pleased to present you with the 8th Across Health Multichannel Maturometer in Life Sciences, which covers the 4 key dimensions of digital maturity: strategy & organization, business processes & technology, multichannel integration and measurement.
If you only look at the averages, the 2016 results are very much a copy-paste of the previous years. At 13%, average satisfaction levels remain at all-time-low levels, while average digital marketing budgets (15.7%) are status-quo for the 4th year running. Skill levels continue to be low, key channels are very similar, etc etc.
However, if you look beyond these averages, some early leaders can be identified. Indeed, 15% states that digital transformation is happening fast. In other words, while most of the eggs in the hatchery are still closed, some “chickens” have already hatched.
We saw the same trend in 2015, where the top 10% is outperforming the average company significantly (http://bit.ly/29qk2lg), except for key “pain points” like mix optimization, campaign management and KPIs.
And if you look at the 2015-2016 comparison (p26), you can again infer that there is some activity in the other eggs too…Indeed, customer databases are increasingly crosschannel, while the pain related to execution (mix planning and campaign management platforms) – and the lack of training - are felt much harder than in 2015…in other words, the other eggs could hatch soon…and MCM will never be the same again!
Happy reading & holidays!
Fonny
Edm forum virtual brown bag presentationMarion Sills
EDM Forum Virtual Brown Bag Presentation 2013
Overview of the SAFTINet Project
For more information on SAFTINet, please see http://www.ucdenver.edu/academics/colleges/medicalschool/programs/outcomes/COHO/saftinet/Pages/default.aspx
Primary care-based, teleretinal-screening protocol (Los Angeles Safety Net) UCLA CTSI
UCLA CTSI-Los Angeles County Department of Health Services (DHS) Projects
Principal Investigators: Lauren Daskivich (DHS), Carol Mangione (UCLA)
Diabetic retinopathy (DR) is the leading cause of blindness among working-age Americans, and among Los Angeles Latinos—the ethnic majority of patients in the Los Angeles County (LAC) safety net—the prevalence of DR is ~50%. Despite evidence that early detection and treatment can prevent blindness from DR, a significant number of persons with diabetes in our system fail to receive annual screening examinations and/or sight-saving treatments due to lack of access to specialty care. To date, the effect of a system level intervention on improving access to eye care and definitive treatment for diabetic retinopathy in an urban medically underserved, or safety net, population has not been evaluated. The objective of this project is to evaluate the impact of teleretinal screening on access to specialty ophthalmic care for diabetic patients in LAC who need monitoring or treatment for diabetic retinopathy. We propose a pre-post analysis of the LAC teleretinal screening implementation, and we aim to evaluate the number of patients screened for diabetic retinopathy, the number presenting for timely ophthalmic follow-up care and treatment, and the cost of the program.
Presentation by John Reites on 08May2015 at the NCHICA Thought Leader Forum on Patient Generated Data in RTP, NC.
The future of health care delivery is connected, continuous, empowered, and personal. Digital capabilities are a foundational element to enable a successful shift to Connected Care and now many organizations are working through how to design, operationalize and sustain a digital care program that provides new and quality access to care to improve outcomes. In addition, organizations must determine how to ingest, analyze, and produce meaningful insight with new forms of data, specifically patient-generated data.
This panel will look at changes in access to care, recent trends in the market place, integration of patient-generated data into healthcare workflows, and the infrastructure (e.g., data lakes) needed to support these powerful new capabilities.
Webinar: Increase research efficiency and enable collaboration with the IDBS ...IDBS
Streamline patient stratification together with omics and sample management
Find out how the solution enables research scientists and clinicians across Healthcare, Pharma and other Life Sciences organizations to create a comprehensive research platform that empowers high quality decision-making. It provides the building blocks to allow clinical researchers to capture and curate their data, to manage ontologies, and to integrate, search and visualize data from clinical, biobanks and omics data sources.
In this webinar you will see how to:
- improve sample management
- capture Data Provenance
- stratify patient populations
- explore omics data in the context of clinical phenotype
- facilitate a results sharing culture between departments and collaborators
To view the webinar: http://www.idbs.com/en/news-events/list-of-webinars/2014/03/increase-research-efficiency-and-enable-collaboration-with-the-idbs-translational-science-solution/
Methods for Observational Comparative Effectiveness Research on Healthcare De...Marion Sills
Research Objective: The SAFTINet project was funded by the AHRQ to build a distributed network of existing clinical and claims data that would support comparative effectiveness research (CER), with a focus on underserved populations and healthcare delivery system (HDS) characteristics. Observational research methods are appropriate, but require detailed protocols with a priori hypotheses and analytic plans. SAFTINet research specifically concerns the effects of a discrete set of HDS features (those often included in Patient-Centered Medical Home (PCMH) models) on health outcomes for primary care patients with asthma, hypertension, and hypercholesterolemia. Our objective is to present a description of this study’s measurement challenges, and to specify a priori hypotheses, analytic strategies, and plans for addressing bias and confounding for our asthma cohorts.
Study Design: An observational, longitudinal cohort study of primary care patients with asthma, with both secondary use of existing clinical and claims data and primary data collection for HDS features and patient- reported outcomes.
Population Studied: Our sample consists of 59 primary care practices in 5 healthcare organizations in Colorado, Utah and Tennessee; all practices serve underserved populations. These practices care for about 275,000 patients per year, of whom an estimated 22,000 have a diagnosis of asthma.
Principal Findings: We will present the processes used to define and measure the HDS features, covariates and asthma outcomes, along with planned analysis. Challenges include valid measurement of a multi-faceted HDS “exposure” variable, the inability to identify exposure onset, and the non-dichotomous nature of HDS characteristics. To measure HDS characteristics, we created a practice-level survey assessing 9 PCMH domains, including care coordination, specialty care and mental health integration, and patient-centeredness, as well as asthma-specific HDS characteristics (e.g., the use of asthma registries). Asthma outcomes included (1) those available as a result of routine electronic documentation of clinical care and claims administration (utilization indicative of an exacerbation), and (2) patient reported outcomes tools (Asthma Control Test). We used directed acyclic graphs to identify potential confounders of the relationship between HDS characteristics and asthma control, as well as other potential biases. The analytic plan is based on linear mixed effects models. Perspectives of the CER team, the technology team and the community engagement group were considered in the operationalization of all variables.
Conclusions: The design of rigorous observational CER observational CER should recognize the need for an intense planning phase. In accordance with good practice guidance for observational studies, an important component of the planning phase is to disseminate and obtain feedback on the research design in advance of its conduct.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-fighting-neurodegenerative-diseases/
Evelyn Pyper, MPH discusses how a patient-centered approach to real-world data collection and evidence generation can transform research in neurodegeneration. Neurodegenerative diseases often affect both motor and cognitive function, produce emotional and social changes, and require significant caregiver support, all while stretching across a fragmented healthcare ecosystem. Participatory research that directly obtains patient consent, empowers patients, and simplifies the task of linking multiple data sources, can lead to a more comprehensive capture of medical histories. This presentation briefly explores ways in which patient-centered research can improve understanding of disease diagnoses, symptomatology, and progression.
Hirshberg promise of digital technology astra_zenecaThe Promise of Digital Te...Levi Shapiro
Presentation by Boaz Hirshberg, VP, Clinical Development, Cardiovascular, Renal, Metabolic Disease at AstraZeneca
- The Promise of Digital Technology in Drug Development Clinical Trials. Includes the following:
- The vision for patient-centric medical care delivery
- End-to-end patient experience enhanced by digital technologies
- Digital technologies have a potential to transform clinical trial & medical care delivery
- Example: transforming our understanding of Type 2 diabetes with remote patient monitoring
- Frequent sampling demonstrates glucose lowering very soon after first dose, which might be unappreciated in typical trial design
- Multiple data points reduce uncertainty about the glucose outcome and enable future machine learning of unanticipated relationships
- Lessons learned from CGM pilot: data storage, transfer, and analysis
- Defining the clinical science questions to be answered
- Operational considerations for incorporating digital data into clinical development
- Addressing challenges of digital technologies’ disruption
Overview of the Patient-Centered Outcomes Research Institute (PCORI), how PCORI views Patient-Centered Outcomes Research and how this is related to PCORI’s major funding mechanisms.
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
From Research to Practice - New Models for Data-sharing and Collaboration to ...Health Data Consortium
Watch the webinar here: http://encore.meetingbridge.com/MB005418/140528/
Webinar transcript: http://hdc.membershipsoftware.org/Files/webinars/HDC-PwC%20NIH%20&%20PCORI%20Webinar%20Transcript%205_28_14.pdf
Patient-Centered Outcomes Research Institute (PCORI) Executive Director Joe Selby, MD, MPH; National Institutes of Health (NIH) Director and PCORI Board of Governors member Francis Collins, MD, PhD; and NIH Associate Director for Data Science Philip Bourne, PhD discussed new and emerging trends in big data for health, including:
- How researchers, patients, clinicians, and others are forging new models for data-sharing.
- Leveraging the quantity, variety, and analytic potential of health-related data for research and practice.
- Addressing patients’ perspectives, needs, and concerns in creating new opportunities for innovation and translational science.
- Exciting initiatives such as PCORnet, the National Patient-Centered Clinical Research Network initiative that PCORI is now helping to develop, and related open data and technology efforts such - as the NIH Health Systems Collaboratory and Big Data to Knowledge (BD2K) initiative.
Discover more health data resources on our website at http://www.healthdataconsortium.org/
Engage and Retain Patients in Long-term Observational StudiesJohn Reites
Traditionally, real-world and late phase studies require sites to enroll, engage and retain patients and collect and record patient reported outcomes (PRO), which can be burdensome to both sites and patients. Overtime, sites and patients may lose motivation to participate, contributing to high patient dropout rates, increased study costs and site dissatisfaction. This session will focus on innovative approaches for effectively engaging and retaining patients in long-term studies, such as: identifying design and operational considerations with conducting long-term observational research, understanding site and patient retention challenges, and examining engagement strategies and opportunities for improving retention and compliance.
The New Health Report 2011 - BackgrounderQuintiles
The New Health Report 2011 is a report based on a national survey of biopharmaceutical executives, managed care executives, physicians and patients living with chronic disease conducted by Richard Day Research of Evanston, Ill., on behalf of Quintiles Transnational Corp. Richard Day Research was responsible for all survey design, data analysis and data reporting. Data for this survey were collected between January 5 and February 27, 2011. Included in the sample were 200 biopharmaceutical executives at the director level or above, 153 managed care executives at the director level or above, 400 primary care physicians, 103 board-certified specialists, and 1,000 U.S. adults ages 18+ diagnosed with a chronic health condition who are receiving treatment.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
3. 3
Patient Involvement in Research
We are being asked to do more with less
Decrease in availability of funds for research
Increase in stakeholder demand for real-world data post-approval
Timelines are being cut
Why we need it…
5. 5
Patient Involvement in Research
Innovation potential for research
Why we need it…
Faster
Enrollment
Increased
Retention
Decreased
Costs
Upfront study design more patient-friendly
Recruitment and retention activities relevant to patients
Patient outreach to supplement recruitment
Patient engagement during study (and beyond)
Remote visits (hybrid virtual study designs)
6. 6
Direct-to-Patient Innovation
*Patient protocol
assessment for
feedback on:
• I/E criteria
• Barriers &
facilitating
messages
*Supplemental
patient
recruitment
*Retention
* Pre-registration
* Alumni
communities
* Direct
recruitment of
patients (no
sites)
* On-line patient
consent &
screening
* Capture of ePRO
data
*Direct outreach to
patients
*Online consent
and ePRO
*Patient consent
for medical record
access
*Patient provision
of DNA or blood
sample
* Device integration
(all without sites)
*Direct patient
outreach & pre-
qualification
*Physician visit for
screening &
randomization
*Remote visits with
ePRO; in-person
visits for physician
endpoints or risk
*Would work well
for pragmatic
trials
Clinical Study
Support
Observational
PRO Data
Observational
PRO+EMR+Lab
+Device
Hybrid Virtual
Clinical Trials
Now Next
8. 8
Balance to Direct-to-Patient
Benefits
> More rapid study launch and
shortened timelines
> Decreased costs compared to
the physician-centric model
> Strong patient interest in method
- Helping others
- Alignment of patient incentives
- Comprehensive condition
monitoring and tracking
> Patient perspective directly
provided
Limitations
> Questions about data quality
- Verification of patient diagnosis
- Self-reported data
- Length of recall
- Lack of randomization
> No physician involvement
> Regulatory requirements in
process of being defined in some
countries
9. 9
Future: Virtual Research
Driving greater efficiencies through direct patient engagement
• Rapid and Efficient Enrollment
> Direct-to-patient recruitment
> On-line screening and consent
• Continued patient engagement
> Retention activities
> Remote lost to follow-up tracking
• Next stage in patient involvement = virtual consent and/or remote patient visits
> Reduces site and patient burden
> Reduces investigator grant fees
> Reduces site monitoring visits
11. 11
Case Study Example:
Burden of Illness in MS Walking Ability
• Walking impairment was associated with
increased falls and severe falls led to
hospitalization/ER use and doctor’s visits
• Objective:
• To assess the clinical,
psychological and economic
impact of differences in walking
ability in patients with MS
• Approach:
• 346 US patients with MS
completed an on-line study in 2
weeks
– PDDS=0: 106 (31%)
– PDDS of >0: 240 (69%)
• Walking ability was significantly
linked to increased:
– Falls
– Depression
– Absenteeism
– Activity restriction
Conclusions
Background Findings Related to Falls
Compliance with Daily Diary (n=74 Subjects)
14%
62%
50%
0%
50%
100%
PDDS 0 PDDS 3 PDDS 4
% of Patients that “Sometimes” Fall
Because of MS by PDDS Score
2% 2%
11% 16%
32% 27%
0%
50%
100%
Hospital / ER Doctor's Office
Resource Utilization for Severe Falls by
PDDS Score
PDDS 0 PDDS 3 PDDS 4
Source: Sidovar M, Horowicz-Mehler N, Hawryluk E, Cascade E, McCarthy S: Patient-Reported Burden of Walking
Impairment in Multiple Sclerosis. ISPOR June 2012.
12. 12
Case Study Example:
PRO + Chart Data in US Gout Patients
• Although concerns exist regarding the
validity of self-reported diagnosis, this
PRO+MR pilot shows nearly all (37 of
38) charts confirm patient data
• Objective: To collect patient-reported
outcomes (PRO) and medical record
(MR) data
• Approach: MediGuard.org members
were invited to participate based upon
treatment or diagnosis in their profile
• Interested members screened based
on self-reported diagnosis and
willingness to release medical records
(electronic and paper signature)
• OHIS contacted physicians and
obtained participant charts
• Results:
• 42 of 50 paper release forms returned
• 38 of 50 charts retrieved (28
electronic, 10 paper)
Conclusions
Background Findings
35 21
0 5 10 15 20 25 30 35
Diagnosis Treatment Missing
% Match from PRO to MR
Medical Records
Source: Cascade E, Marr P; Tuttle D, Winslow M: Patient-Reported Outcomes (PRO) and Medical Record Data (MR) in
Observational Study Designs: Results from a Direct-to-Patient Pilot Study in Gout. ISPOR June 2012.
13. 13
Case Study Example:
Measuring UK Real-World Outcomes
• Quintiles patient consent & connectivity
provide opportunity for intervention
• PRO+EMR environment serves as
foundation for intervention evaluation
• Objective: Build a UK data-rich
environment to measure outcomes
• Approach: Conducted study to
demonstrate PRO+EMR link with
SAIL data warehouse in Wales, UK
• In 6 weeks, recruited 240
cholesterol patients who
completed PRO assessments and
consented to share identifiers
• Identifiers provided to NHS Wales
to create pseudo-identifier bridge
into SAIL data warehouse
o PRO data combined with
electronic data stored in SAIL at
Swansea Univ. for all Wales
Conclusions
93% 98%
0%
25%
50%
75%
100%
Patients
(224 of 240)
Diagnosis
(89 of 91)
Background Findings
% Match from PRO to EMR Wales, UK
Source: Cascade E, Nixon M, Ford D, Brooks C, Heaven M: Combining Electronic Health Records and Patient-Reported
Information in the UK: Preliminary Results from the WASPS (Wales SAIL + PRO Study) . ISPOR June 2012.
14. 14
Case Study Example:
Evidence-based Program Design
• Data-driven patient framework
serves as the foundation for
program design
• Design includes continuous
program evaluation component
• Objective: Build HTN engagement
program around deep
understanding of patient drivers
• Approach: Surveyed >350 patients
in UK, DE, ES, IT to support design:
• Behavioral segments
o Control: External / Internal
o Emotion: Positive / Negative
o Agency/Action: High / Low
• Validated patient-reported
outcomes instruments used to
evaluate adherence, treatment
satisfaction, and other drivers of
engagement
• Communication preferences:
Content, Message, Frequency
Results
51%
39% 39%
24% 23% 21%
13%
8%
0%
20%
40%
60%
IPH EPL EPH IPL INH ENH ENL INL
% Perfect Adherence by Segment
Background Findings
Source: Cascade E, Cousins F, Connor U, Sandy R: Variance in Medication Adherence by Patient Behavioral Segment: A Multi-
Country Study in Hypertension . ISPOR June 2012.